Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

Rachelle S. Doody; Ronald G. Thomas; Martin R. Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul Aisen; Eric Siemers; Hong Liu‐Seifert; Richard C. Mohs

doi:10.1056/nejmoa1312889

Abstract

Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 ClinicalTrials.gov numbers, NCT00905372 and NCT00904683.).

Keywords

MedicinePlaceboAlzheimer's diseaseInternal medicineConfidence intervalOncologyDiseasePathology

MeSH Terms

Activities of Daily LivingAgedAged80 and overAlzheimer DiseaseAmyloid beta-PeptidesAntibodiesMonoclonalHumanizedApolipoproteins EBiomarkersCognitionDouble-Blind MethodFemaleHumansIntention to Treat AnalysisMaleNeuropsychological TestsSeverity of Illness IndexTreatment Failuretau Proteins

Affiliated Institutions

Related Publications

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Christoph Wanner , Silvio E. Inzucchi , John M. Lachin +7 more

In patients with type 2 diabetes at high cardiovascular risk, empagliflozin was associated with slower progression of kidney disease and lower rates of clinically relevant renal...

2016 New England Journal of Medicine 3470 citations

Donanemab in Early Alzheimer’s Disease

Mark A. Mintun , Albert Lo , Cynthia Evans +10 more

In patients with early Alzheimer's disease, donanemab resulted in a better composite score for cognition and for the ability to perform activities of daily living than placebo a...

2021 New England Journal of Medicine 1451 citations

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman , Christoph Wanner , John M. Lachin +9 more

Patients with type 2 diabetes at high risk for cardiovascular events who received empagliflozin, as compared with placebo, had a lower rate of the primary composite cardiovascul...

2015 New England Journal of Medicine 11369 citations

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

David R. Boulware , Matthew F Pullen , Ananta Bangdiwala +21 more

After high-risk or moderate-risk exposure to Covid-19, hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure proph...

2020 New England Journal of Medicine 1395 citations

Publication Info

Year: 2014
Type: article
Volume: 370
Issue: 4
Pages: 311-321
Citations: 1588
Access: Closed

External Links

Download PDF (Free) View on DOI.org PubMed Semantic Scholar

Social Impact

Altmetric

Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1588

OpenAlex

Influential

1394

CrossRef

Cite This

APA Style

                            
                                
                                    Rachelle S. Doody, 
                                
                                    Ronald G. Thomas, 
                                
                                    Martin R. Farlow
                                
                                et al.
                            
                            (2014). 
                            Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease. 
                            New England Journal of Medicine
                            , 370
                            (4)
                            , 311-321.
                            https://doi.org/10.1056/nejmoa1312889
                        

Identifiers

DOI: 10.1056/nejmoa1312889
PMID: 24450890

Data Quality

Data completeness: 86%